TG2 promotes amyloid beta aggregates: Impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer's disease

Panes-Fernandeza, Jessica; Godoy, Pamela A.; Gavilan, Javiera; Ramirez-Molina, Oscar; Burgos, Carlos Felipe; Marileo, Ana; Flores-Nunez, Oscar; Castro, Patricio A.; Moraga-Cid, Gustavo; Yevenes, Gonzalo E.; Munoz-Montesino, Carola; Fuentealba, Jorge


Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by cognitive impairment that increasingly affects the elderly. AD's main features have been related to cellular and molecular events, including the aberrant aggregation of the amyloid beta peptide (A ss), Ca2+ dyshomeostasis, and increased mitochondriaassociated membranes (MAMs). Transglutaminase type 2 (TG2) is a ubiquitous enzyme whose primary role is the Ca2+-dependent proteins transamidation, including the A ss peptide. TG2 activity has been closely related to cellular damage and death. We detected increased TG2 levels in neuronal cells treated with A ss oligomers (A ss Os) and hippocampal slices from J20 mice using cellular and molecular approaches. In this work, we characterized the capacity of TG2 to interact and promote A ss toxic aggregates (A ss TG2). A ss TG2 induced an acute increase in intracellular Ca2+, miniature currents, and hiperexcitability, consistent with an increased mitochondrial Ca2+ overload, IP3R-VDAC tethering, and mitochondria-endoplasmic reticulum contacts (MERCs). A ss TG2 also decreased neuronal viability and excitatory postsynaptic currents, reinforcing the idea of synaptic failure associated with MAMs dysregulation mediated by TG2. Z-DON treatment, TG2 inhibitor, reduced calcium overload, mitochondrial membrane potential loss, and synaptic failure, indicating an involvement of TG2 in a toxic cycle which increases A ss aggregation, Ca2+ overload, and MAMs upregulation. These data provide novel information regarding the role TG2 plays in synaptic function and contribute additional evidence to support the further development of TG2 inhibitors as a disease-modifying strategy for AD.

Más información

Título según WOS: ID WOS:001057836700001 Not found in local WOS DB
Volumen: 162
Fecha de publicación: 2023


Notas: ISI